Sergei Polevikov, Abd, Mba, Ms, Ma 🇮🇱🇺🇦 Email & Phone Number

New York, Ny, Us

I'm proud that my job as an academic peer reviewer in the field of artificial intelligence (AI) applied to genetics plays a crucial role in ensuring the quality, validity, and reliability of scientific research. My primary responsibilities include: evaluating the research, assessing its novelty and significance, identifying flaws and errors, providing constructive feedback, ensuring ethical standards, and communicating with editors. I take pride in maintaining the high standards of academic research and ensuring that published studies contribute meaningful and valid scientific findings.As a Peer Reviewer at Springer for The European Journal of Human Genetics, I contribute to a premier publication of the European Society of Human Genetics. The journal is dedicated to publishing high-quality, original research papers, short reports, and reviews in the rapidly evolving field of human genetics and genomics. My specific role involves applying my expertise in artificial intelligence to the genetics domain, ensuring the validity and quality of research presented in this niche. The journal encompasses molecular, clinical, and cytogenetic studies, acting as a crucial interface between advanced biomedical research and clinical practitioners. My work further supports the journal's commitment to bridging the considerable diversity of facilities, resources, and perspectives within the global genetics community.

The WG-AIGD working group was established in response to the COVID-19 pandemic. Our aim was to explore how we, as scientists, could utilize AI and other emerging technologies in genomic diagnostics and broader clinical medicine. Some group members previously conducted the inaugural academic review of technologies emerging to combat COVID-19, resulting in the highly cited paper "Artificial Intelligence-Powered Search Tools and Resources in the Fight Against COVID-19," published on June 2, 2020. My contribution involved examining various AI tools employed to tackle COVID-19 and elucidating their specific applications. One such tool was WellAI's COVID-19 Research Tool, which enables medical researchers to find efficient, often non-trivial ways to apply their expertise towards addressing COVID-19.The group recognized the vital importance of addressing ethical issues and best practices concerning the application of AI in clinical practice. I took the lead on this project, which resulted in an academic opinion review titled "Advancing AI in Healthcare: A Comprehensive Review of Best Practices." The review concluded that while AI possesses significant potential to enhance patient care, it also introduces risks and challenges such as maintaining privacy, battling bias, and upholding transparency and ethics. The report emphasizes the importance of promoting diverse dialogue amongst data scientists, clinicians, patient advocates, ethicists, economists, and policymakers.Currently, my focus is on developing IFCC-GPT, a version of ChatGPT dedicated to medical research. The model undergoes an initial fine-tuning process using extensive digitized datasets of medical Q&As, followed by the ingestion of tens of thousands of selected medical research articles. The model merges this trained knowledge to answer researchers' and doctors' questions in a conversational manner, potentially answering questions that have never been posed before, by synthesizing the available data.

New York City Metropolitan Area

🎯 Spearheaded the development of an AI-assisted Digital Front Door ecosystem for clinics and hospitals.🎯 Led product security and ensured HIPAA compliance.🎯 Managed successful AWS integration for efficient app function and operation.🎯 Maintained and validated AI algorithm code to ensure optimal functionality.

New York City Metropolitan Area

I take great pride in the achievements made by my team and myself at WellAI. Founded amidst the COVID-19 pandemic, WellAI aimed to streamline the interaction between patients and doctors. We aspired to alleviate the burden on doctors by automating their workflow, summarizing notes and patients' medical histories, and providing an AI-based platform for diagnosis and treatment.I oversaw the development of WellAI’s COVID-19 application, a vital tool for medical researchers battling the virus. Furthermore, I championed the creation of a comprehensive AI-assisted Digital Front Door ecosystem for clinics and hospitals. This unique AI platform facilitates a 30-second AI-assisted scientific triage for patients. Our Digital Front Door platform encompasses services like Telehealth, Nurse Chat, Medication Refill, Lab/Test Results, Access to Medical Records, Visual Medical Summary, and Healthcare Wallet, thus significantly reducing patient wait times.In my role as CEO, I have made countless phone calls, composed hundreds of thousands of emails, and negotiated with a myriad of venture capitalists, esteemed investors, vendors, partners, and customers. The relentless efforts of my team have enabled our unique AI technology to assist thousands of patients and a host of clinicians every day.WellAI is revolutionizing primary care and optimizing hospital workflow solutions through comprehensive voice-guided scientific triage, AI-based telehealth, convenient telehealth scheduler, compliant nurse chat, automatic clinician note generation, along with an exceptionally accurate AI diagnostic tool - all within the AWS-based HIPAA-compliant platform.Harnessing insights from over 30 million medical studies, and still counting, our AI precision model boasts an accuracy rate of 83% for top-three diagnoses based on 2,400 vignettes (sets of symptoms). WellAI notably reduces a patient's onboarding time from the US national average of 23 minutes to just 7 minutes.

I've served on Administration, Budget & Audit Committee.From its inception in 1966, the Q Group (The Institute for Quantitative Research in Finance) has provided a forum for investment professionals to advance the practice of global investment management by connecting investment professionals with rigorous research and ideas at the frontier of the industry.With an interest in research for applications (rather than the theoretical), the Q Group celebrates research that demonstrates a grounded logic and a disciplined scientific methodology in finance, economics and those crossing disciplines. Through its semi-annual seminars, the Q Group provides opportunities for investment professionals to learn about new research in quantitative finance from leading scholars working in the field.Internationally recognized, the Q Group seminars offer a forum where those working in the industry can engage the academic community in a spirited dialogue of cutting-edge theory and its potential value in real life applications.

My teaching responsibilities focus on equipping the young leaders of Belarus with up-to-date knowledge of economic principles and contemporary investment models.

Greater New York City Area

During my 12-year tenure on the SQA board, I had the privilege of collaborating with some of the most distinguished professionals in the quantitative finance industry. I was actively involved in every SQA seminar and conference, recommending innovative research, inviting respected speakers, and assisting with event logistics, from liaising with venues and speakers to designing promotional material.Three events from my tenure stand out. The first followed the infamous AXA-Rosenberg case brought by the Securities and Exchange Commission (SEC). Amid industry debates on potential SEC double standards, I proposed a panel discussion. Despite the challenge of inviting the SEC and AXA-Rosenberg's CEO to discuss an ongoing investigation and coordinating schedules for nine panelists, we managed to host a successful event with significant industry players. The conference, "Model Risk, Quants and the Law", drew approximately 300 senior finance professionals, becoming one of SQA's most successful events.I'm also immensely proud of the “Sustainable Investing” conference, our response to the rising trend of Environmental, Social, and Governance (ESG) investing. Urging the board to scrutinize this trend, we invited experts to present varied perspectives. This conference, attended by about 100 investment professionals, brought together academics, industry experts, environmental advocates, and Nobel Laureate Robert Schiller, marking a significant milestone in my career and the field of ESG.Finally, organizing SQA’s ‘Fuzzy Day’ Conference and a gala for its 50th anniversary embodied teamwork and in-depth research into the organization's history. After meticulously reviewing archival material and tracing former SQA presidents, we managed to assemble an extraordinary cohort of 21 past SQA leaders. This event served as a grand celebration of SQA's enduring legacy in quantitative finance.

New York, New York, United States

I participated in every SQA event, actively contributing by discussing research topics and suggesting potential speakers.

New York, United States

🎯 Served as lead developer for smart beta ETFs (tickers: OMFL and OMFS), with approximately $4.4 billion in assets under management (AUM).🎯 Collaboratively developed and co-managed GMAT alternative risk premia strategies, overseeing a portfolio of approximately $150 million.🎯 Achieved recognition as the employee of the year in 2017, receiving the prestigious Donald W. Spiro Award.

New York, United States

🎯 Performed as the lead developer for OppenheimerFunds' strategic allocation strategies, managing approximately $5 billion in assets under management (AUM).🎯 Served as lead portfolio manager for quantitative funds (tickers: OAPPX, OAPMX, OAPRX), overseeing approximately $900 million in AUM.

New York, United States

🎯 Managed risks for retail and institutional portfolios utilizing multi-asset risk models (BarraOne, Aladdin, RiXtrema) and equity risk models (Barra, Northfield, Thomson/Vestek, Axioma).🎯 Conducted security modeling for derivatives, including equity and FX options, FX forwards, futures, convertibles, TRS, IRS, MBS, and PERCs.🎯 Executed fair value modeling and shareholder flow forecasts across OppenheimerFunds' portfolios.🎯 Developed a mathematical model for predicting Morningstar ratings, utilized as a key insight by OppenheimerFunds' marketing department.🎯 Demonstrated proficiency in Python, Matlab, SQL, and Visual Basic (VBA).🎯 Gained experience in employing Bloomberg, FactSet, CRSP, Lipper, Morningstar, Ibbotson (Encorr) platforms, BarraOne, Northfield, ThomsonOne, and Global Financial Data (GFD).

I had the privilege of working alongside the Chief Economist and President of the bank on numerous research projects. These included the studies of inflation indices, living standards, energy pricing, and the role of technological innovation in driving the economy. As a team member and statistician, I am proud to have contributed to the Pulitzer Prize-nominated book, "Myths of Rich & Poor: Why We’re Better Off Than We Think," authored by W. Michael Cox and Richard Alm.

Master Of Business Administration - Mba, Finance

Master Of Arts - Ma, Economics

Master'S Degree, Applied Economics

Phd-Equivalence, Applied Mathematics